Cell-based Parkinson's disease therapy - Titan Pharmaceuticals

Drug Profile

Cell-based Parkinson's disease therapy - Titan Pharmaceuticals

Alternative Names: Spheramine; TC-15

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Titan Pharmaceuticals
  • Developer Bayer Schering Pharma; Titan Pharmaceuticals
  • Class Antiparkinsonians; Cell therapies; Gene therapies; Neuroprotectants
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 02 Jul 2008 Suspended - Phase-II for Parkinson's disease in USA (Intrastriatal)
  • 30 Apr 2008 Four-year, follow-up efficacy and safety data from a clinical trial in patients with moderate-to-advanced Parkinson's disease released by Titan Pharmaceuticals
  • 19 Apr 2008 Pharmacodynamics data from a primate model of Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top